MX2022007968A - Dosificacion de gamma-hidroxibutirato (ghb). - Google Patents

Dosificacion de gamma-hidroxibutirato (ghb).

Info

Publication number
MX2022007968A
MX2022007968A MX2022007968A MX2022007968A MX2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A MX 2022007968 A MX2022007968 A MX 2022007968A
Authority
MX
Mexico
Prior art keywords
ghb
hydroxybutyrate
dosing
gamma
narcolepsy
Prior art date
Application number
MX2022007968A
Other languages
English (en)
Inventor
Franck Skobieranda
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2022007968A publication Critical patent/MX2022007968A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente memoria se proporcionan métodos para administrar formulaciones de GHB para el tratamiento de la narcolepsia y otras afecciones.
MX2022007968A 2019-12-24 2020-12-22 Dosificacion de gamma-hidroxibutirato (ghb). MX2022007968A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US202063052676P 2020-07-16 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (1)

Publication Number Publication Date
MX2022007968A true MX2022007968A (es) 2022-09-02

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007968A MX2022007968A (es) 2019-12-24 2020-12-22 Dosificacion de gamma-hidroxibutirato (ghb).

Country Status (14)

Country Link
US (2) US20210186907A1 (es)
EP (1) EP4081204A1 (es)
JP (1) JP2023508975A (es)
KR (1) KR20220119429A (es)
CN (1) CN115209885A (es)
AU (1) AU2020414694A1 (es)
BR (1) BR112022012594A2 (es)
CA (1) CA3162974A1 (es)
CL (1) CL2022001743A1 (es)
CO (1) CO2022010330A2 (es)
IL (1) IL294176A (es)
MX (1) MX2022007968A (es)
TW (1) TW202135790A (es)
WO (1) WO2021133778A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012024019B1 (pt) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE238783T1 (de) 1998-12-23 2003-05-15 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
US7015200B2 (en) 2000-09-22 2006-03-21 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
CO2022010330A2 (es) 2022-10-21
CL2022001743A1 (es) 2023-02-10
US20210361601A1 (en) 2021-11-25
KR20220119429A (ko) 2022-08-29
BR112022012594A2 (pt) 2022-09-06
EP4081204A1 (en) 2022-11-02
IL294176A (en) 2022-08-01
AU2020414694A1 (en) 2022-08-18
CA3162974A1 (en) 2021-07-01
CN115209885A (zh) 2022-10-18
TW202135790A (zh) 2021-10-01
WO2021133778A1 (en) 2021-07-01
US20210186907A1 (en) 2021-06-24
JP2023508975A (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
GEP20237506B (en) Pcsk9 antagonist compounds
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EA202190377A9 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
GEP20227443B (en) Magl inhibitors
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021015411A (es) Composiciones acopladoras especificas de macrofagos y metodos de uso de las mismas.
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
PH12020551716A1 (en) Anti-ror antibody constructs
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2022001004A (es) Inhibidores de enzimas.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
GEP20247585B (en) Furoindazole derivatives
ZA202001756B (en) Oral care compositions
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2021016050A (es) Formulaciones transdermicas.
MX2022000811A (es) Inhibidores de enzimas.